Brief: Carisma Therapeutics On June 26, Notified Novartis Pharmaceuticals Of Termination Of Co's Manufacturing & Supply Agreement Between Co & Novartis

Carisma Therapeutics

02/07/2024 22:01

July 2 (Reuters) - Carisma Therapeutics Inc  CARM.O :
    * CARISMA THERAPEUTICS : ON JUNE 26, NOTIFIED NOVARTIS
PHARMACEUTICALS OF TERMINATION OF CO'S MANUFACTURING & SUPPLY
AGREEMENT BETWEEN CO & NOVARTIS
    * CARISMA THERAPEUTICS INC -  TERMINATION OF CO'S
MANUFACTURING
AND SUPPLY AGREEMENT, BY AND BETWEEN CO AND NOVARTIS IS
EFFECTIVE JULY 31, 2024
    * CARISMA THERAPEUTICS - CO DETERMINED TO FOCUS EX VIVO
ONCOLOGY
CLINICAL DEVELOPMENT EFFORTS ON ITS FOLLOW-ON PRODUCT CANDIDATE
CT-0525
    * CARISMA THERAPEUTICS INC - HAS SUSPENDED ENROLLMENT OF NEW
PATIENTS IN ITS PHASE 1 CLINICAL TRIAL FOR CT-0508

Source text for Eikon:  ID:n0001104659-24-077372 
Further company coverage:  CARM.O 

 ((Reuters.Briefs@thomsonreuters.com;))